Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Commercial Officer | May 02, 2024 | May 06, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 02, 2024 · Filed May 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,767 |
Ending reported balance
After 2024-05-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-30 · Grant · Acquired 300 · Balance 71,767 F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Row 2 · 2024-05-02 · Sale · Disposed 5,000 · Balance 66,767 F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,277 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 4,277 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 26, 2026 00:18 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 4,000 | $0.00 Strike: $57.66 | $0.00 |
DisclosureSEC source: 0001193125-26-403097 · ownership.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2034-09-22 F4 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. Read SEC document |
| September 23, 2026 Filed Sep 26, 2026 00:18 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-403097 · ownership.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,277 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 23, 2026. F3 · balance_after: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 32,341 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001193125-26-294560 · ownership.xml · derivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,341 Underlying: Common Stock · 32,341 shares Expires 2036-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 23:49 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 8,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001193125-25-227232 · ownership.xml · derivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:43 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000950170-25-093102 · ownership.xml · derivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:26 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $11.78 | $0.00 |
DisclosureSEC source: 0000950170-25-052530 · ownership.xml · derivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-04-07 F1 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document |
| September 18, 2024 Filed Jan 18, 2025 01:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 120,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-006880 · ownership.xml · derivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-09-17 F1 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 18, 2024. Read SEC document |
| May 02, 2024 Filed May 6, 2024 20:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $82.91 | $414,550.00 |
DisclosureSEC source: 0001048477-24-000073 · wk-form4_1715028037.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,767 F2 · date: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. Read SEC document |
| April 30, 2024 Filed May 6, 2024 20:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 300 | $68.65 | $20,593.80 |
DisclosureSEC source: 0001048477-24-000073 · wk-form4_1715028037.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,767 F1 · date: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 22,580 | $83.87 | $1,893,784.60 |
DisclosureSEC source: 0001048477-24-000036 · wk-form4_1710894971.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,467 Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $87.07 | $348,280.00 |
DisclosureSEC source: 0001048477-24-000030 · wk-form4_1709850751.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,047 F1 · date: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:12 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000022 · wk-form4_1709244737.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,047 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:12 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000022 · wk-form4_1709244737.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,582 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:12 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 21,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000022 · wk-form4_1709244737.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,244 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 00:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 85,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-23-050220 · doc4.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-09-18 F2 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023. Read SEC document |
| September 18, 2023 Filed Sep 21, 2023 00:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,359 | $0.69 | $3,007.71 |
DisclosureSEC source: 0001209191-23-050220 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,153 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a "sell to cover" transaction. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 19:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $90.00 | $450,000.00 |
DisclosureSEC source: 0001048477-23-000039 · wk-form4_1692302235.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,804 F2 · date: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. Read SEC document |
| April 28, 2023 Filed Aug 17, 2023 19:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 318 | $66.88 | $21,267.20 |
DisclosureSEC source: 0001048477-23-000039 · wk-form4_1692302235.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,804 F1 · date: Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 16, 2023 Filed Mar 18, 2023 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 20,510 | $93.41 | $1,915,839.10 |
DisclosureSEC source: 0001567619-23-005283 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,486 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 23,070 | $0.00 Strike: $87.74 | $0.00 |
DisclosureSEC source: 0001567619-23-005283 · doc1.xml · derivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,070 Underlying: Common Stock · 23,070 shares Expires 2033-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,971 | $87.74 | $348,415.54 |
DisclosureSEC source: 0001567619-23-005283 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,996 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-005283 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,967 F1 · price: Restricted stock units granted on March 15, 2023. Price not applicable. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 7,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014609 · doc4.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,857 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014609 · doc4.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,228 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 20,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014609 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,848 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 02:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 46,800 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-001396 · doc1.xml · derivative · entry 5 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,800 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 02:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,200 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-001396 · doc1.xml · derivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,200 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 02:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,175 | $116.15 | $484,942.95 |
DisclosureSEC source: 0001567619-23-001396 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,088 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 02:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 44,825 | $115.65 | $5,184,190.55 |
DisclosureSEC source: 0001567619-23-001396 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,263 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 02:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 49,000 | $67.81 | $3,322,690.00 |
DisclosureSEC source: 0001567619-23-001396 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 21:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,000 | $86.12 | $258,360.00 |
DisclosureSEC source: 0001567619-22-019207 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,088 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| September 23, 2022 Filed Sep 26, 2022 23:25 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,198 | $3.16 | $13,265.68 |
DisclosureSEC source: 0001209191-22-051304 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,512 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a "sell to cover" transaction. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:41 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,400 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-22-050808 · doc4.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2030-09-15 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:41 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050808 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,710 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 16, 2022. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 23:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,000 | $95.62 | $286,860.00 |
DisclosureSEC source: 0001567619-22-015887 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,088 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 18:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,021 | $77.49 | $544,057.29 |
DisclosureSEC source: 0001567619-22-012432 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,088 Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 01:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,308 | $78.94 | $103,253.52 |
DisclosureSEC source: 0001567619-22-011966 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,109 F2 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| April 29, 2022 Filed Jun 1, 2022 01:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 340 | $62.41 | $21,218.38 |
DisclosureSEC source: 0001567619-22-011966 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,417 F1 · date: Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 23:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,180 | $82.47 | $97,314.60 |
DisclosureSEC source: 0001567619-22-008576 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,077 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,381 | $79.56 | $109,872.36 |
DisclosureSEC source: 0001567619-22-007808 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,257 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,618 | $79.43 | $128,517.74 |
DisclosureSEC source: 0001567619-22-007808 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,638 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 00:49 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,129 | $81.78 | $501,229.62 |
DisclosureSEC source: 0001567619-22-007460 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,256 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| March 22, 2022 Filed Mar 25, 2022 00:49 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,073 | $81.00 | $167,913.00 |
DisclosureSEC source: 0001567619-22-007460 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,385 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 01:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,287 | $80.72 | $103,886.64 |
DisclosureSEC source: 0001567619-22-007177 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,458 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 28,670 | $0.00 Strike: $78.27 | $0.00 |
DisclosureSEC source: 0001567619-22-007177 · doc1.xml · derivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,670 Underlying: Common Stock · 28,670 shares Expires 2032-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2023 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 8,418 | $78.27 | $658,876.86 |
DisclosureSEC source: 0001567619-22-007177 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,745 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007177 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,163 F1 · price: Restricted stock units granted on March 15, 2022. Price not applicable. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006713 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,223 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return for 2019 through 2021 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 100% vests on March 15, 2022, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 23:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,739 | $73.60 | $201,590.40 |
DisclosureSEC source: 0001567619-21-018936 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,853 F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,400 | $0.00 Strike: $17.78 | $0.00 |
DisclosureSEC source: 0001209191-21-057702 · doc4.xml · derivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2029-09-21 F4 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.